The clinical trials delays have emerged as the main concern for the pharmaceutical and healthcare industry after the ongoing coronavirus pandemic disrupted more than 1,200 clinical trials across the world.
GlobalData conducted a survey among pharmaceutical companies to identify their main concerns related to clinical trials in 2020.
Primary Clinical Trial Concerns Related to the Covid-19 Outbreak
The survey found that 30% of the respondents highlighted that the inability or delay to initiate clinical trials was the highest clinical trial-related concern.
Impact on clinical trial participants (26%) and safety of the patients recruited in trials (24%) were the second and third biggest concerns, respectively.
Around 11% of the respondents highlighted that negative impact on planned statistical goals submitted to agencies was the main concern, while another 7% opined loss of investment as the main concern.
Another 2% of the companies opined that they had other concerns related to clinical trials amid COVID-19.
The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.